All articles tagged with #jandj
A promising antiviral drug called mosnodenvir has shown effectiveness in preventing dengue infection, but Johnson & Johnson has abandoned its development, leaving a critical gap in treatment options as dengue spreads globally due to climate change.
The European Society for Medical Oncology (ESMO) has released data from high-profile presentations several days early due to a broken embargo on the abstracts. The decision was made to ensure fair and equitable access to the data for all relevant parties. The release includes data from Bristol Myers, J&J, Novartis, and AstraZeneca.
By taking advantage of the odd lot rule, investors can potentially make over $1,000 in just two weeks by purchasing 99 shares of J&J stock.
SoFi, J&J, Ford, XPeng, Wayfair, Adobe, and more are among the stocks that are making significant moves in the stock market.
J&J and Legend Biotech's CAR-T therapy, Carvykti, showed a 74% reduction in the risk of disease progression or death for adults with multiple myeloma who had received between one and three previous treatments. However, it remains to be seen how many patients will take the therapy and when it will become widely available.
Johnson & Johnson has paid $245m upfront for global development and commercialisation rights to two early-stage, autologous CAR-T therapy programmes from CBMG, which has a track record of allying itself with the biggest names in the development world. Astellas Pharma is to buy Iveric Bio for $5.9bn in cash, while Pfizer is focusing on M&A and oncology as Covid sales decline. The US government's court battle has begun over Gilead HIV drug patents, while Boehringer Ingelheim is to construct a $300m+ facility at its HQ. Sanofi is using its sponsorship of the Paris Olympics to encourage employees to find their potential, while Novo Nordisk is teaming up with a professional soccer player living with type 1 diabetes to highlight the possibilities of a life with the chronic disease.
Johnson & Johnson's CAR-T therapy, Carvykti, developed in partnership with Legend Biotech, has shown a 74% reduction in the risk of multiple myeloma progression or death, according to leaked abstract data. The results could put Carvykti ahead of competitor Abecma, developed by Bristol Myers Squibb and 2seventy bio, in earlier lines of treatment if and when it's approved for those indications. The study's results surprised analysts, with a Cowen analyst describing it as "game-changing efficacy," and sent Legend's shares 14% higher after Wednesday's opening bell.
Bank of America, Goldman Sachs, J&J, Lockheed, and Netflix are among the stocks that are moving the most today in the stock market.
J&J, FedEx, Albemarle, and C3.ai are among the stocks that are moving the most in the stock market today.